Jefferies Underperform on AMAG Pharmaceuticals

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Jefferies & Co. is out with a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and it has an Underperform rating and a $12 price target on shares.In a note to clients, Jefferies & Co. writes, "Management changes and expense alignment (vs. slow Feraheme sales) are positive. However, shareholders could be better served if AMAG divests Feraheme, returns its value & current cash (~$11.8/sh) to shareholders, in our view. Excluding $3M in Medicaid reserve estimate, 3Q11 Feraheme sales of $12.8M (~flat q/q). Our revenue estimate changes are due to failed merger with ALTH (removing Folotyn estimates)."Shares of AMAG are up $2.48 to $16.23, a gain of 18.04%‎.

27% profits every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!